Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

Kawabata, Ryohei; Wada, Hisashi; Isobe, Midori; Sakaguchi, Takashi; Sato, Kimiyasu; Uenaka, Akiko; Miyata, Hiroshi; Yasuda, Takushi; Doki, Yuichiro; Noguchi, Yuji; Kumon, Hiromi; Tsuji, Kazuhide; Iwatsuki, Keiji; Shiku, Hiroshi; Ritter, Gerd; Murphy, Roger; Hoffman, Eric W.; Old, Lloyd J.; Monden, Morito; Nakayama, Eiichi

doi:10.1002/ijc.22583

Cited by 71 publications

(78 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 The regions in the NY-ESO-1 molecule recognized by antibodies from vaccinated patients were similar to those recognized by antibodies in nonvaccinated cancer patients with spontaneous immunity. Especially, we showed that NY-ESO-1 91-108 was recognized in six of nine vaccinated patients and in eight of nine nonvaccinated, seropositive patients.…”

mentioning

confidence: 79%

A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen

Kakimi

Isobe

Uenaka

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 lg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.The NY-ESO-1 antigen was originally identified in esophageal cancer by serological expression cloning (SEREX) using autologous patient serum.1,2 NY-ESO-1 expression is observed in a wide range of human malignancies, 3,4 but the expression is restricted to germ cells in the testes in normal adult tissues. 1,3Therefore, NY-ESO-1 has emerged as a prototype of a class of cancer/testis (CT) antigens. 5More than 100 patients with NY-ESO-1-expressing tumors have received the NY-ESO-1 vaccine either as fulllength recombinant protein given as protein alone, with ISCOMATRIX V R or cholesterol-bearing hydrophobized pullulan (CHP), delivered in a recombinant vaccinia or fowlpox vector, or as the NY-ESO-1b peptide given with various adjuvants. [6][7][8][9][10][11] These studies established safety with various preparations of the NY-ESO-1 vaccine, showing toxicity to be limited to Grade 1 or 2 injection-site reactions or flu-like

show abstract

mentioning

confidence: 79%

A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen

Kakimi

Isobe

Uenaka

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is more likely that detection of NY-ESO-1 immunity may be a surrogate for a more general immune activation to multiple targets, which may have allowed for a favorable clinical outcome. Several recent reports have shown that vaccination with NY-ESO-1 as a recombinant protein, formulated either with saponin-based adjuvant ISCOMATRIX or with cholesterol-bearing hydrophobized pullulan, induced strong NY-ESO-1 antibody as well as CD4 ϩ and CD8 ϩ responses in the majority of patients (28)(29)(30)(31). It is reasonable to consider combining such vaccines with ipilimumab in an attempt to induce an integrated immune response to NY-ESO-1.…”

Section: Discussionmentioning

confidence: 99%

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Yuan¹,

Gnjatic

Li³

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

326

246

View full text Add to dashboard Cite

“…We also detected MAGE-A3-specific CD8 ϩ T cell responses in patients who developed the highest-titered broadly specific antibody responses after vaccination. So far, few trials have been conducted in which recombinant proteins were used as immunogen in cancer vaccines (12)(13)(14)(15)(16), and if T cell responses have been reported, they consisted mainly of CD4 ϩ T cells (17,18). Two reports have shown that vaccination with CT antigen NY-ESO-1 as a recombinant protein, formulated either with saponin-based adjuvant ISCOMATRIX or with cholesterol-bearing hydrophobized pullulan, induced strong antibody as well as CD4 ϩ and CD8 ϩ responses in the majority of patients (19,20).…”

Section: Discussionmentioning

confidence: 99%

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

Atanackovic

Altorki

Cao

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

144

107

View full text Add to dashboard Cite

We previously reported results of a phase II trial in which recombinant MAGE-A3 protein was administered with or without adjuvant AS02B to 18 non-small-cell lung cancer (NSCLC) patients after tumor resection. We found that the presence of adjuvant was essential for the development of humoral and cellular responses against selected MAGE-A3 epitopes. In our current study, 14 patients that still had no evidence of disease up to 3 years after vaccination with MAGE-A3 protein with or without adjuvant received an additional four doses of MAGE-A3 protein with adjuvant AS02B. After just one boost injection, six of seven patients originally vaccinated with MAGE-A3 protein plus adjuvant reached again their peak antibody titers against MAGE-A3 attained during the first vaccination. All seven patients subsequently developed even stronger antibody responses. Furthermore, booster vaccination widened the spectrum of CD4 ϩ and CD8 ؉ T cells against various new and known MAGE-A3 epitopes. In contrast, only two of seven patients originally vaccinated with MAGE-A3 protein alone developed high-titer antibodies to MAGE-A3, and all these patients showed very limited CD4 ؉ and no CD8 ؉ T cell reactivity, despite now receiving antigen in the presence of adjuvant. Our results underscore the importance of appropriate antigen priming using an adjuvant for generating persistent B and T cell memory and allowing typical booster responses with reimmunization. In contrast, absence of adjuvant at priming compromises further immunization attempts. These data provide an immunological rationale for vaccine design in light of recently reported favorable clinical responses in NSCLC patients after vaccination with MAGE-A3 protein plus adjuvant AS02B.antibody ͉ CD4 ϩ T cell ͉ CD8 ϩ T cell ͉ immunization ͉ non-small-cell lung cancer

show abstract

Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

Cited by 71 publications

References 21 publications

A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen

A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

Contact Info

Product

Resources

About